IL100088A - FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8 - Google Patents

FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8

Info

Publication number
IL100088A
IL100088A IL10008891A IL10008891A IL100088A IL 100088 A IL100088 A IL 100088A IL 10008891 A IL10008891 A IL 10008891A IL 10008891 A IL10008891 A IL 10008891A IL 100088 A IL100088 A IL 100088A
Authority
IL
Israel
Prior art keywords
tnf
xanthine
pharmaceutical composition
formula
group
Prior art date
Application number
IL10008891A
Other languages
English (en)
Hebrew (he)
Other versions
IL100088A0 (en
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL100088A0 publication Critical patent/IL100088A0/xx
Publication of IL100088A publication Critical patent/IL100088A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dentistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pest Control & Pesticides (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL10008891A 1990-11-21 1991-11-19 FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8 IL100088A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61647990A 1990-11-21 1990-11-21

Publications (2)

Publication Number Publication Date
IL100088A0 IL100088A0 (en) 1992-08-18
IL100088A true IL100088A (en) 1995-07-31

Family

ID=24469639

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10008891A IL100088A (en) 1990-11-21 1991-11-19 FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8

Country Status (14)

Country Link
EP (1) EP0558659A4 (ref)
JP (1) JP3204971B2 (ref)
KR (1) KR930702896A (ref)
AP (1) AP259A (ref)
AU (1) AU656938B2 (ref)
CA (1) CA2096623A1 (ref)
HU (1) HUT65838A (ref)
IE (1) IE914034A1 (ref)
IL (1) IL100088A (ref)
MX (1) MX9102173A (ref)
NZ (1) NZ240644A (ref)
TW (1) TW222001B (ref)
WO (1) WO1992009203A1 (ref)
ZA (1) ZA919178B (ref)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
AU7376394A (en) * 1993-08-04 1995-02-28 Andrulis Pharmaceuticals Corporation Use of tumor necrosis factor inhibitors together with antiviral agents and therapeutic compositions thereof against hiv infection
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
CA2506949A1 (en) * 2002-11-27 2004-06-10 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
HRP20130406T1 (hr) 2004-02-14 2013-06-30 Glaxosmithkline Intellectual Property Development Limited Medikamenti s aktivnošä†u prema receptoru hm74a
RU2395511C2 (ru) * 2004-02-14 2010-07-27 Смитклайн Бичам Корпорейшн Новые соединения
JP5112316B2 (ja) 2005-08-10 2013-01-09 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
CN107001371B (zh) 2014-10-09 2019-07-05 广东众生睿创生物科技有限公司 羟基嘌呤类化合物及其应用
EP3369733B1 (en) * 2015-10-29 2020-01-15 Guangdong Raynovent Biotech Co., Ltd. Crystal form of 4h-pyrazolo[1,5- ]benzoimidazole compound, preparation method therefor and intermediate thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US757328A (en) * 1903-02-07 1904-04-12 Boehringer & Soehne Art of preparing xanthin derivatives.
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
CH654008A5 (fr) * 1979-05-22 1986-01-31 Nestle Sa Procede de preparation de 1,3,7-trialkylxanthines.
DE2944568A1 (de) * 1979-11-05 1981-05-14 Institut für industrielle Pharmazie F + E GmbH, 8750 Aschaffenburg Pharmazeutische zubereitung
IT1200944B (it) * 1982-08-10 1989-01-27 Malesci Sas Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
GB8610136D0 (en) * 1986-04-25 1986-05-29 Wellcome Found Compounds
IT1197516B (it) * 1986-12-24 1988-11-30 Abc Ist Biolog Chem Spa Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5015647A (en) * 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
FI891419A7 (fi) * 1989-03-23 1990-09-24 Tampella Oy Ab Anordning i en gaengoeppningsanordning foer borrmaskineri.

Also Published As

Publication number Publication date
MX9102173A (es) 1992-06-01
ZA919178B (en) 1992-10-28
HUT65838A (en) 1994-07-28
EP0558659A1 (en) 1993-09-08
AU656938B2 (en) 1995-02-23
JP3204971B2 (ja) 2001-09-04
IL100088A0 (en) 1992-08-18
AP9100335A0 (en) 1992-01-31
KR930702896A (ko) 1993-11-29
WO1992009203A1 (en) 1992-06-11
HU9301509D0 (en) 1993-11-29
NZ240644A (en) 1994-08-26
TW222001B (ref) 1994-04-01
CA2096623A1 (en) 1992-05-22
IE914034A1 (en) 1992-06-03
AU9115991A (en) 1992-06-25
AP259A (en) 1993-06-03
JPH06506192A (ja) 1994-07-14
EP0558659A4 (en) 1993-10-20

Similar Documents

Publication Publication Date Title
EP0542795B1 (en) Tnf inhibitors
AP259A (en) Inhibitors for tumor necrosis factor (TNF) based 8-substituted xanthines.
US6767908B2 (en) Substituted imidazoles having cytokine inhibitory activity
HUP0001358A2 (hu) QT diszperzió és szívverés változékonyság javítása CRF antagonista hatású heterociklusos vegyületek alkalmazásával hirtelen halál megelőzése céljából
JPH11510156A (ja) キノロン類およびその医療上の使用
AU2004273610A1 (en) Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
HUP0204079A2 (hu) Szedatív hatástól mentes antihisztaminok és leukotrién hatást befolyásoló anyagok új kombinációja orrnyálkahártya-gyulladás, vagy kötőhártya-gyulladás kezelésére
JP2002521436A (ja) 置換アニリド化合物および方法
EP0572537B1 (en) Cytokine inhibitors
WO2000069829A1 (en) Method of inhibiting neurotrophin-receptor binding
JP2023528722A (ja) サイトカインストーム症候群及び関連疾患を治療する方法
US5547979A (en) TNF inhibition
CN1260784A (zh) 作为pdeiv和tnf抑制剂的喹啉衍生物
WO1993016699A1 (en) Tnf inhibitors
CN102753172A (zh) 用于治疗痴呆的5-ht4受体激动剂
WO2019225741A1 (ja) インドール化合物を含むネフローゼ症候群の治療又は予防剤
EA007952B1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
WO2004054616A1 (ja) ケモカイン受容体の強結合部位に結合するアンタゴニストおよびアゴニスト
EP1054669B1 (en) Use of thiadiazolo[4,3-a]pyridine derivatives
PT100429B (pt) Uso de derivados da xantina na preparacao de um medicamento para inibicao da producao de factor de necrose tumoral
US7858612B2 (en) Therapeutic agent for inflammatory bowel diseases
KR20000035861A (ko) Ａｉｄｓ 치료용 약제를 제조하기 위한 ｐｋｃ 억제제의 사용 방법
JPH10503178A (ja) Ｈｉｖ感染のための組合わせ療法
WO2021224494A1 (en) New treatments of viral infections
JPH08502044A (ja) ヒトウイルス感染の治療

Legal Events

Date Code Title Description
RH Patent void